This company listing is no longer active
B8FE Stock Overview
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.26 |
| 52 Week High | €4.74 |
| 52 Week Low | €1.26 |
| Beta | 1.27 |
| 11 Month Change | 2.73% |
| 3 Month Change | 32.94% |
| 1 Year Change | -48.64% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| B8FE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -11.7% | -4.6% | -1.2% |
| 1Y | -48.6% | -19.2% | 9.0% |
Return vs Industry: B8FE underperformed the German Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: B8FE underperformed the German Market which returned -25.6% over the past year.
Price Volatility
| B8FE volatility | |
|---|---|
| B8FE Average Weekly Movement | 31.8% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: B8FE's share price has been volatile over the past 3 months.
Volatility Over Time: B8FE's weekly volatility has increased from 26% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 98 | Hermann Lubbert | www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria.
Biofrontera AG Fundamentals Summary
| B8FE fundamental statistics | |
|---|---|
| Market cap | €78.27m |
| Earnings (TTM) | €10.45m |
| Revenue (TTM) | €30.77m |
7.5x
P/E Ratio2.5x
P/S RatioIs B8FE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B8FE income statement (TTM) | |
|---|---|
| Revenue | €30.77m |
| Cost of Revenue | €4.67m |
| Gross Profit | €26.10m |
| Other Expenses | €15.65m |
| Earnings | €10.45m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 84.82% |
| Net Profit Margin | 33.95% |
| Debt/Equity Ratio | 0.5% |
How did B8FE perform over the long term?
See historical performance and comparison